Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIRKER: Preoperative Imatinib in Rectal GIST
NCT05970900Phase 3Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of imatinib in gastrointestinal stromal tumor (GIST), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Organ preservation at 18 months. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT05970900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05970900.